What if we could use gene editing to treat Duchenne Muscular Dystrophy—not just manage symptoms, but address the underlying genetic cause in a scalable, precise way?

In this episode, Dr. Courtney Young, CEO of MyoGene Bio, shares how her company is using CRISPR technology to transform the treatment landscape for Duchenne Muscular Dystrophy, offering hope to patients and families facing this devastating disease.

What we discuss:

• The vision behind MyoGene Bio and why Duchenne Muscular Dystrophy

• How CRISPR gene editing works and why it's uniquely suited for Duchenne

• Scalability, precision, and safety considerations in gene editing therapies

• Navigating the regulatory pathway for CRISPR-based treatments

• Fundraising in the gene editing space and building investor confidence

• Leadership and culture: building a mission-driven biotech company

• Personal reflections on the future of gene therapy and rare disease treatment

This isn't just about treating one disease. This is about proving what's possible when gene editing meets rare disease—and opening the door for countless others.

About the Guest: Dr. Courtney Young is CEO of MyoGene Bio, a gene therapy company developing CRISPR-based treatments for Duchenne Muscular Dystrophy.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• MyoGene Bio: [https://www.myogenebio.com]

• Courtney Young: [https://www.linkedin.com/in/courtney-young-mgb]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #CRISPR #GeneEditing #DuchenneMuscularDystrophy #RareDisease #GeneTherapy #PrecisionMedicine #Innovation

What if gene editing could treat Duchenne Muscular Dystrophy at its genetic root—not just manage symptoms?

Dr. Courtney Young, CEO of MyoGene Bio, is using CRISPR to address the underlying cause of Duchenne in a scalable, precise way that could transform rare disease treatment.

🎙️ Full episode drops September 11

In the complete interview, we dive into:

• Why CRISPR is uniquely suited for Duchenne

• Scalability, precision, and safety in gene editing

• Navigating regulatory pathways

• The future of gene therapy for rare diseases

Subscribe so you don't miss it.

#SneakPeek #CRISPR #GeneEditing #RareDisease

What if we could destroy cancer cells using a completely novel payload—one that doesn't rely on traditional chemotherapy or even antibody-drug conjugates, but instead uses lytic peptides to obliterate tumors?

In this episode, Dr. Stanley Lewis, CEO of A28 Therapeutics, shares how his company is pioneering lytic peptides as a next-generation cancer therapy, offering a fundamentally different approach to killing cancer cells.

What we discuss:

• The vision behind A28 Therapeutics and the science of lytic peptides

• How lytic peptides work differently from traditional cancer payloads

• Why this approach could overcome resistance mechanisms that limit other therapies

• The role of AI and machine learning in drug discovery and peptide design

• Fundraising strategies and building investor confidence in novel modalities

• Leadership and culture: assembling a team to tackle cancer differently

• Personal reflections on the future of oncology and transformative therapeutics

This isn't another antibody-drug conjugate. This is a completely different way to kill cancer.

About the Guest: Dr. Stanley Lewis is CEO of A28 Therapeutics, a biotechnology company developing novel lytic peptide-based cancer therapeutics.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• A28 Therapeutics: [https://a28therapeutics.com]

• Stanley Lewis: [https://www.linkedin.com/in/stanley-t-lewis-md-mph]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #Cancer #Oncology #LyticPeptides #DrugDiscovery #ArtificialIntelligence #NovelTherapeutics #Innovation

What if we could destroy cancer cells using a completely novel payload that doesn't rely on traditional chemotherapy or even antibody-drug conjugates?

Dr. Stanley Lewis, CEO of A28 Therapeutics, is pioneering lytic peptides as a next-generation cancer therapy—a fundamentally different way to kill tumors.

🎙️ Full episode drops August 28

In the complete interview, we dive into:

• How lytic peptides work differently from traditional payloads

• Overcoming resistance mechanisms

• The role of AI in peptide design

• Building A28 Therapeutics

Subscribe so you don't miss it.

#SneakPeek #Cancer #LyticPeptides #DrugDiscovery

What if we could transform the treatment landscape for rheumatologic diseases by taking bold, innovative approaches that go beyond incremental improvements?

In this episode, Dr. James Mackay, CEO of Crystalys Therapeutics, shares the vision behind launching a new biotech company focused on rheumatology, combining next-generation science with strategic leadership to address unmet patient needs.

What we discuss:

• The vision behind Crystalys Therapeutics and why rheumatology

• New approaches and innovative strategies in treating rheumatologic diseases

• Approach to risk management in early-stage biotech

• Fundraising strategies and building investor confidence from day one

• Leadership and culture: assembling the right team for a startup biotech

• Navigating the competitive landscape in rheumatology

• Personal reflections on entrepreneurship and the future of autoimmune disease treatment

This isn't just another rheumatology company. This is about bringing transformative science to patients who desperately need better options.

About the Guest: Dr. James Mackay is CEO of Crystalys Therapeutics, a biotechnology company developing novel therapeutics for rheumatologic diseases.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• Crystalys Therapeutics: [https://crystalystx.com]

• James Mackay: [https://www.linkedin.com/in/james-m-mackay]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #Rheumatology #AutoimmuneDisease #DrugDevelopment #Innovation #Startup #BiotechLeadership

What does it take to launch a biotech company with bold, innovative approaches to rheumatologic diseases?

Dr. James Mackay, CEO of Crystalys Therapeutics, is bringing next-generation science and strategic leadership to patients who desperately need better treatment options.

🎙️ Full episode drops August 14

In the complete interview, we dive into:

• The vision behind Crystalys Therapeutics

• New approaches in treating rheumatologic diseases

• Risk management in early-stage biotech

• Fundraising and building the right team

Subscribe so you don't miss it.

#SneakPeek #Rheumatology #Biotech #AutoimmuneDisease

What does it take to transform bold ideas into real-world treatments that save lives?

Welcome to Innovating Tomorrow's Medicine, a podcast that goes beyond the headlines to explore the strategies, insights, and breakthroughs shaping the future of healthcare and biotechnology.

Hosted by Dr. Jeff Trickett—a neuroscientist and biotech strategist—this show features candid conversations with biotech founders, CEOs, researchers, and innovators who are tackling medicine's biggest challenges. From AI-driven diagnostics to gene editing, novel cancer therapies, and precision medicine, each episode delivers substantive discussions about the science, strategy, and leadership driving transformative change.

What you'll discover:

• The vision and science behind breakthrough therapies

• Real talk about fundraising, clinical development, and commercialization

• Leadership insights from those building the future of medicine

• How innovation happens—from lab bench to patient impact

🧬 Bold ideas.

🧠 Visionary innovators.

💡 The science of tomorrow in focus today.

Whether you're in biotech, healthcare, or simply fascinated by medical innovation, this podcast uncovers the strategies behind success and the breakthroughs that will define the future of medicine.

🎧 Subscribe now and join the conversation.

About the Host: Dr. Jeff Trickett is a neuroscientist, biotech strategist, and business development leader with experience spanning drug development, commercial strategy, and portfolio management across biopharma and life sciences.

🔗 Connect:

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

• Website: [https://pointlomabiopharma.com]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #Healthcare #Innovation #DrugDevelopment #LifeSciences #Podcast #MedicalInnovation #PrecisionMedicine